Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Liraglutide

Saxenda

Stage Approved

Sponsor Novo Nordisk A/S

Route oral and injection

Class GLP-1 RA

Mechanism Phentermine-Topiramate

Sources

registry, as of 2018-01-19Stale

https://clinicaltrials.gov/study/NCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 3731. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Fu Change From Baseline in Fasting Body Weight Liraglutide 3.0 mg (56-Week) -7.98 percent change Week 0, Week 56 Change From Baseline in Fasting Body Weight Liraglutide Placebo (56-Week) -2.62 percent change Week 0, Week 56 Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight. Liraglutide 3.0 mg (56-Week) 63.2

ClinicalTrials.gov NCT01272219 protocol and results modules

registry, as of 2017-12-29Stale

https://clinicaltrials.gov/study/NCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 846. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subj Change (%) From Baseline in Body Weight (Fasting) Liraglutide 3.0 mg -5.9 percent change Week 0, week 56 Change (%) From Baseline in Body Weight (Fasting) Liraglutide 1.8 mg -4.6 percent change Week 0, week 56 Change (%) From Baseline in Body Weight (Fasting) Liraglutide Placebo -2.0 percent change Week 0, week 56 Proportion of Subjects Losing at Least 5% of Baseli

ClinicalTrials.gov NCT01272232 protocol and results modules

registry, as of 2017-11-01Stale

https://clinicaltrials.gov/study/NCT00781937

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 422. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pres Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 Lira 3.0 mg 50.5 Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 Placebo 21.9 Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 Lira 3.0 mg 26.1 Percentage of Subjects Who Lost More Than 10% of Fasting

ClinicalTrials.gov NCT00781937 protocol and results modules

registry, as of 2023-06-07Stale

https://clinicaltrials.gov/study/NCT04605861

The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Shanghai Zhongshan Hospital. Enrollment 414. Conditions Obese; Overweight. This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect and safety of Liraglutide Injection on body weight loss compared with placebo in obese or overweight adult patients with comorbidity of metabolic disorders.

ClinicalTrials.gov NCT04605861 protocol and results modules

registry, as of 2020-03-30Stale

https://clinicaltrials.gov/study/NCT02963922

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 396. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin. Change in Body Weight (%) In-trial observation period Liraglutide 3.0 mg -6.0 Percentage change Week 0, week 56 Change in Body Weight (%) In-trial observation period Placebo -1.5 Percentage change Week 0, week 56 Change in Body Weight (%) On-drug observation period Liraglutide 3.0 mg -6.5 Percentage change Week 0, week 56 Change in Body Weight (%) On-drug observation period Placebo -1.7 Percentage change Wee

ClinicalTrials.gov NCT02963922 protocol and results modules

registry, as of 2017-11-01Stale

https://clinicaltrials.gov/study/NCT01557166

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 359. Conditions Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea. This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea. Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) Liraglutide 3.0 mg -0.36 percentage of glycosylated haemoglobin Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) Placebo -0.17 percentage of glycosylated haemoglobin diarrhoea Liraglutide 3.0 mg 29 nausea Liraglutide 3.0 mg 47 vomiting Liraglutide 3.0 mg 13 diarrhoea Placebo 14 nausea Placebo 12 vomiting Placebo 5

ClinicalTrials.gov NCT01557166 protocol and results modules

registry, as of 2023-05-19Stale

https://clinicaltrials.gov/study/NCT04074161

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 338. Conditions Overweight; Obesity. This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will e Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Semaglutide 2.4 mg -16.4 Percentage of body weight Baseline (week 0), week 68 Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) Liraglutide 3.0 mg -6.4 Percentage of body weight Baseline (week 0), week 68 Chan

ClinicalTrials.gov NCT04074161 protocol and results modules

registry, as of 2020-08-25Stale

https://clinicaltrials.gov/study/NCT04525300

Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 300. Conditions Obesity. We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either lir

ClinicalTrials.gov NCT04525300 protocol and results modules

registry, as of 2020-07-27Stale

https://clinicaltrials.gov/study/NCT04487743

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 300. Conditions Obesity. We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either lir

ClinicalTrials.gov NCT04487743 protocol and results modules

registry, as of 2020-03-11Stale

https://clinicaltrials.gov/study/NCT02963935

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 282. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obe Change in Body Weight (%) In-trial observation period Liraglutide 3.0 mg -7.4 percent change Week 0, week 56 Change in Body Weight (%) In-trial observation period Placebo -4.0 percent change Week 0, week 56 Change in Body Weight (%) On-drug observation period Liraglutide 3.0 mg -9.1 percent change Week 0, week 56 Change in Body Weight (%) On-drug o

ClinicalTrials.gov NCT02963935 protocol and results modules

registry, as of 2020-04-27Stale

https://clinicaltrials.gov/study/NCT02918279

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 251. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity. Change in Body Weight (%) Change from week 0 to week 30 Liraglutide 3.0 mg -4.3 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 to week 30 Placebo 0.4 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 to week 56 Liraglutide 3.0 mg -3.2 Percentage change (Week 0, week 30); (Week 0, week 56); (Week 56, week 82) Change in Body Weight (%) Change from week 0 t

ClinicalTrials.gov NCT02918279 protocol and results modules

registry, as of 2023-07-18Stale

https://clinicaltrials.gov/study/NCT03374956

Individualized Obesity Pharmacotherapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor Mayo Clinic. Enrollment 193. Conditions Obesity. The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss. deaths Intervention Group 0 deaths Control Group 0

ClinicalTrials.gov NCT03374956 protocol and results modules

registry, as of 2023-10-23Stale

https://clinicaltrials.gov/study/NCT05952882

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Mỹ Đức Hospital. Enrollment 188. Conditions Polycystic Ovary Syndrome; Obesity; Infertility, Female. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the leading causes of infertility. PCOS and obesity affect up to 12.5% - 48.3% Asian women, increase incidence of impaired glucose tolerance, type 2 diabetes and aggrava

ClinicalTrials.gov NCT05952882 protocol and results modules

registry, as of 2026-08-25Stale

https://clinicaltrials.gov/study/NCT05965908

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome. Overall status COMPLETED. Phases PHASE3. Lead sponsor Beni-Suef University. Enrollment 183. Conditions Polycystic Ovary. The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.

ClinicalTrials.gov NCT05965908 protocol and results modules

registry, as of 2019-07-26Stale

https://clinicaltrials.gov/study/NCT01234649

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM). Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 153. Conditions Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation. A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. S Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline) Metformin XR Plus Liraglutide -7.2 percent change in weight from baseline Change from baseline (time 0) to study end (84 weeks) Change in Body Weight From Baseline to End of Study (Expressed as % Com

ClinicalTrials.gov NCT01234649 protocol and results modules

registry, as of 2020-01-30Stale

https://clinicaltrials.gov/study/NCT02043054

Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA). Overall status COMPLETED. Phases PHASE3. Lead sponsor University of Leicester. Enrollment 90. Conditions Type 2 Diabetes Mellitus; Cardiovascular Disease. There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors. Both of these therapies target the incretin system using different methods to elevate/maintain circulating levels of GLP1 to sub

ClinicalTrials.gov NCT02043054 protocol and results modules

registry, as of 2021-06-07Stale

https://clinicaltrials.gov/study/NCT03480022

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS. Overall status COMPLETED. Phases PHASE3. Lead sponsor Woman's. Enrollment 88. Conditions Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android. There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS). Given that PCOS is a frequent condition and weight loss is essential but difficult to achieve, it is important to study if the effect on bo Change in Percent Body Weight Liraglutide Pen Injector (Saxenda) 5.7 percentage loss in body weight Change from baseline (time 0) to study end (32 weeks) Change in Percent Body Weight Placebo Liraglutide Pen Injector 1.4 percentage loss in body weight Change from baseline (time 0) to study end (32 weeks) deaths Liraglutide Pen Injector (Saxenda) 0 nausea

ClinicalTrials.gov NCT03480022 protocol and results modules

registry, as of 2019-12-17Stale

https://clinicaltrials.gov/study/NCT01753362

Liraglutide In Overweight Patients With Type 1 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor University at Buffalo. Enrollment 84. Conditions Type 1 Diabetes. The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin. deaths Placebo 0 deaths Liraglutide 0

ClinicalTrials.gov NCT01753362 protocol and results modules

registry, as of 2026-07-09Stale

https://clinicaltrials.gov/study/NCT04775082

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 78. Conditions Obesity. The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either ge

ClinicalTrials.gov NCT04775082 protocol and results modules

registry, as of 2021-04-09Stale

https://clinicaltrials.gov/study/NCT03986008

Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Xiangya Hospital of Central South University. Enrollment 60. Conditions Obesity. The purpose of this studay is to evaluate the effects of Benaglutide on the treatment of subjects with obesity.

ClinicalTrials.gov NCT03986008 protocol and results modules

registry, as of 2023-07-06Stale

https://clinicaltrials.gov/study/NCT02527200

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 56. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part A: Liraglutide -1.7 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part A: Placebo -0.7 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part B: Liraglutide -1.1 Percent change in body weight Week 0, week 16 Change in Body Weight (Percentage [%]) From Baseline at Week 16 Part B: Placebo -2.2 Perc

ClinicalTrials.gov NCT02527200 protocol and results modules

registry, as of 2018-01-30Stale

https://clinicaltrials.gov/study/NCT02654665

Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Changi General Hospital. Enrollment 36. Conditions Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH). Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, or hereditary

ClinicalTrials.gov NCT02654665 protocol and results modules

registry, as of 2016-03-24Stale

https://clinicaltrials.gov/study/NCT02718950

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans. Overall status UNKNOWN. Phases PHASE3. Lead sponsor University of Campinas, Brazil. Enrollment 20. Conditions Obesity; Type 2 Diabetes Mellitus. The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.

ClinicalTrials.gov NCT02718950 protocol and results modules

registry, as of 2020-03-27Stale

https://clinicaltrials.gov/study/NCT04325581

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Post Graduate Institute of Medical Education and Research, Chandigarh. Enrollment 16. Conditions Weight Loss. Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than either of them individually. However there are no s

ClinicalTrials.gov NCT04325581 protocol and results modules

registry, as of 2022-06-30Stale

https://clinicaltrials.gov/study/NCT02417103

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid. Overall status TERMINATED. Phases PHASE3. Lead sponsor Universitätsklinikum Hamburg-Eppendorf. Enrollment 2. Conditions Obesity. The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.

ClinicalTrials.gov NCT02417103 protocol and results modules

registry, as of 2024-09-26Stale

https://clinicaltrials.gov/study/NCT04683237

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia. Overall status WITHDRAWN. Phases PHASE2,PHASE3. Lead sponsor Xiaojun Chen. Enrollment 0. Conditions Atypical Endometrial Hyperplasia; Obese; Fertility Issues. To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

ClinicalTrials.gov NCT04683237 protocol and results modules

registry, as of 2020-04-17Stale

https://clinicaltrials.gov/study/NCT02453711

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 957. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.05 mg 53.5 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.1 mg 67.49 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.2 mg 74.91 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.3 mg 80.52 Participants With Weight Loss of ≥5% of Baseline Body Weight Semaglutide 0.4 mg 82.52 Participants With Weight Loss of ≥5% of Baseline Body

ClinicalTrials.gov NCT02453711 protocol and results modules

registry, as of 2020-08-17Stale

https://clinicaltrials.gov/study/NCT03235050

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 834. Conditions Diabetes Mellitus, Type 2. This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% Placebo 3.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 100 mcg 18.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 200 mcg 65.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% MEDI0382 300 mcg 92.0 Percentage of Participants Achieving Weight Loss of ≥5% and ≥10% Placebo 11.0 Percentage of Participants Achieving Weight Loss

ClinicalTrials.gov NCT03235050 protocol and results modules

registry, as of 2024-07-05Stale

https://clinicaltrials.gov/study/NCT03856047

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 706. Conditions Overweight; Obesity. This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more phys Change in Body Weight (%) Cagrilintide 0.3 mg -6.1 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 0.6 mg -6.9 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 1.2 mg -8.5 Percentage point of body weight From baseline (week 0) to week 26 Change in Body Weight (%) Cagrilintide 2.4

ClinicalTrials.gov NCT03856047 protocol and results modules

registry, as of 2017-11-01Stale

https://clinicaltrials.gov/study/NCT00422058

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 564. Conditions Metabolism and Nutrition Disorder; Obesity. This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial period Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira Placebo/Lira 2.4 mg/Lira 3.0 mg 5.6 percentage (%) of total haemoglobin Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira 1.2 mg/Lira 3.0 mg 5.58 percentage (%) of total haemoglobin Change From Baseline in HbA1c (Glycosylated Haemoglobin A1c) at Week 20 Lira 1.8 mg/Lira 3.0 mg 5.6 percentage (%)

ClinicalTrials.gov NCT00422058 protocol and results modules

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143

Use The safety and effectiveness of SAXENDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management have been established in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m 2 or greater for a

DailyMed saxenda, indication text

Studies

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Registry NCT01272219

EudraCT 2008-001049-24

Phase Phase 3

Status Completed

Enrollment 3731

Start 2011-06-01

Primary completion 2013-03-18

Study completion 2015-03-02

Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)

Dose 3.0mg

Regimen once daily

Weeks 68

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, 0.69 %, week 56Stale

Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)

Dose 3.0mg

Regimen once daily

Weeks 68

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, 2.91 %, week 56Stale

Liraglutide Placebo, no Pre-diabetes

Regimen once daily

Weeks 68

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, 0.28 %, week 56Stale

participants with diarrhoea, 46 participantsStale

participants with nausea, 78 participantsStale

participants with vomiting, 25 participantsStale

Liraglutide 3.0mg, Pre-diabetes

Dose 3.0mg

Regimen once daily

Weeks 68

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Liraglutide Placebo, Pre-diabetes

Regimen once daily

Weeks 68

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -2.62 %Stale

participants with at least 5 percent body weight loss, 27.1 %, week 56Stale

participants with at least 10 percent body weight loss, 10.6 %, week 56Stale

participants with at least 5 percent body weight loss, 23.7 %, week 160Stale

participants with diarrhoea, 107 participantsStale

participants with nausea, 128 participantsStale

participants with vomiting, 42 participantsStale

Liraglutide 3.0 mg (56-Week)

Dose 3.0 mg

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -7.98 %Stale

participants with at least 5 percent body weight loss, 63.2 %, week 56Stale

participants with at least 10 percent body weight loss, 33.1 %, week 56Stale

participants with at least 5 percent body weight loss, 49.6 %, week 160Stale

participants with diarrhoea, 388 participantsStale

participants with nausea, 622 participantsStale

participants with vomiting, 300 participantsStale

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Registry NCT01272232

EudraCT 2008-002199-88

Phase Phase 3

Status Completed

Enrollment 846

Start 2011-06-01

Primary completion 2013-01-01

Study completion 2013-01-25

Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 56

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -5.9 %Stale

participants with at least 5 percent body weight loss, 49.9 %, week 56Stale

participants with at least 10 percent body weight loss, 23.4 %, week 56Stale

change in HbA1c, -1.3 percentage point change of HbA1cStale

percent change in body weight, 2.3 %, week 56Stale

participants with diarrhoea, 108 participantsStale

participants with nausea, 138 participantsStale

participants with vomiting, 66 participantsStale

Lira 1.8 mg

Dose 1.8 mg

Regimen once daily

Weeks 56

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -4.6 %Stale

participants with at least 5 percent body weight loss, 35.6 %, week 56Stale

participants with at least 10 percent body weight loss, 14.4 %, week 56Stale

change in HbA1c, -1.1 percentage point change of HbA1cStale

percent change in body weight, 2 %, week 56Stale

participants with diarrhoea, 37 participantsStale

participants with nausea, 66 participantsStale

participants with vomiting, 21 participantsStale

Placebo

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -2 %Stale

participants with at least 5 percent body weight loss, 13.8 %, week 56Stale

participants with at least 10 percent body weight loss, 4.3 %, week 56Stale

change in HbA1c, -0.3 percentage point change of HbA1cStale

percent change in body weight, -0.1 %, week 56Stale

participants with diarrhoea, 27 participantsStale

participants with nausea, 29 participantsStale

participants with vomiting, 12 participantsStale

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Registry NCT00781937

Phase Phase 3

Status Completed

Enrollment 422

Start 2008-10-30

Primary completion 2010-09-01

Study completion 2010-09-01

Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

participants with at least 5 percent body weight loss, 50.5 %Stale

participants with at least 10 percent body weight loss, 26.1 %Stale

participants with nausea, 101 participantsStale

participants with diarrhoea, 38 participantsStale

participants with vomiting, 35 participantsStale

Placebo

Regimen once daily

Population Metabolism and Nutrition Disorder; Obesity

participants with at least 5 percent body weight loss, 21.9 %Stale

participants with at least 10 percent body weight loss, 6.3 %Stale

participants with nausea, 36 participantsStale

participants with diarrhoea, 26 participantsStale

participants with vomiting, 5 participantsStale

The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

Registry NCT04605861

Phase Phase 3

Status Completed

Enrollment 414

Start 2020-08-18

Primary completion 2022-12-31

Study completion 2023-04-15

Liraglutide

Regimen once daily

Weeks 7

Comparator placebo

Population Obese; Overweight

Placebo

Regimen once daily

Weeks 7

Population Obese; Overweight

SCALE™ Insulin

Registry NCT02963922

EudraCT 2015-005619-33

Phase Phase 3

Status Completed

Enrollment 396

Start 2017-02-06

Primary completion 2018-09-10

Study completion 2018-09-25

liraglutide 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 56

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -6 %Stale

participants with at least 5 percent body weight loss, 51.8 %, week 56Stale

participants with at least 10 percent body weight loss, 22.77 %, week 56Stale

change in HbA1c, -1.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 45 participantsStale

participants with nausea, 58 participantsStale

participants with vomiting, 32 participantsStale

Placebo

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -1.5 %Stale

participants with at least 5 percent body weight loss, 23.98 %, week 56Stale

participants with at least 10 percent body weight loss, 6.55 %, week 56Stale

change in HbA1c, -0.5 Percentage of HbA1cStale

deaths

participants with diarrhoea, 30 participantsStale

participants with nausea, 23 participantsStale

participants with vomiting, 12 participantsStale

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Registry NCT01557166

Phase Phase 3

Status Completed

Enrollment 359

Start 2012-06-07

Primary completion 2013-06-01

Study completion 2013-06-17

Liraglutide 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 32

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea

change in HbA1c, -0.36 percentage of glycosylated haemoglobinStale

participants with diarrhoea, 29 participantsStale

participants with nausea, 47 participantsStale

participants with vomiting, 13 participantsStale

Placebo

Regimen once daily

Weeks 32

Population Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea

change in HbA1c, -0.17 percentage of glycosylated haemoglobinStale

participants with diarrhoea, 14 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 5 participantsStale

STEP 8

Registry NCT04074161

Phase Phase 3

Status Completed

Enrollment 338

Start 2019-09-11

Primary completion 2021-03-27

Study completion 2021-05-11

Semaglutide

Regimen once weekly

Weeks 68

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -16.4 %Stale

change in HbA1c, -0.3 Percenatge of HbA1cStale

Placebo (semaglutide)

Regimen once weekly

Weeks 68

Population Overweight; Obesity

Liraglutide

Regimen once weekly

Weeks 68

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -6.4 %Stale

change in HbA1c, -0.1 Percenatge of HbA1cStale

Placebo (liraglutide)

Regimen once weekly

Weeks 68

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -1.6 %Stale

change in HbA1c, 0.1 Percenatge of HbA1cStale

deaths

participants with diarrhoea, 22 participantsStale

participants with nausea, 19 participantsStale

participants with vomiting, 5 participantsStale

Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities

Registry NCT04525300

Phase Phase 3

Enrollment 300

Start 2020-05-24

Liraglutide

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

placebo

Regimen once daily

Weeks 28

Population Obesity

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

Registry NCT04487743

Phase Phase 3

Enrollment 300

Start 2020-05-09

Liraglutide

Regimen once daily

Weeks 28

Comparator placebo

Population Obesity

placebo

Regimen once daily

Weeks 28

Population Obesity

SCALE™ IBT

Registry NCT02963935

Phase Phase 3

Status Completed

Enrollment 282

Start 2017-02-06

Primary completion 2018-05-23

Study completion 2018-06-19

Liraglutide

Regimen once daily

Weeks 56

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -7.4 %Stale

Placebo

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -4 %Stale

Liraglutide 3.0 mg, in trial

Dose 3.0 mg

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 61.47 %, week 56Stale

participants with at least 10 percent body weight loss, 30.45 %, week 56Stale

participants with at least 15 percent body weight loss, 18.11 %, week 56Stale

change in HbA1c, -0.2 percentageStale

deaths

participants with diarrhoea, 31 participantsStale

participants with nausea, 68 participantsStale

participants with vomiting, 33 participantsStale

Placebo, in trial

Regimen once daily

Weeks 56

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 38.82 %, week 56Stale

participants with at least 10 percent body weight loss, 19.75 %, week 56Stale

participants with at least 15 percent body weight loss, 8.92 %, week 56Stale

change in HbA1c, -0.1 percentageStale

deaths

participants with diarrhoea, 23 participantsStale

participants with nausea, 25 participantsStale

participants with vomiting, 7 participantsStale

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Registry NCT02918279

EudraCT 2014-004353-14

Phase Phase 3

Status Completed

Enrollment 251

Start 2016-09-29

Primary completion 2019-02-14

Study completion 2019-08-08

Liraglutide

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -4.3 %Stale

change in HbA1c, -0.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 28 participantsStale

participants with nausea, 53 participantsStale

participants with vomiting, 43 participantsStale

Placebo

Regimen once daily

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, 0.4 %Stale

change in HbA1c, 0 Percentage of HbA1cStale

deaths

participants with diarrhoea, 18 participantsStale

participants with nausea, 18 participantsStale

participants with vomiting, 5 participantsStale

Individualized Obesity Pharmacotherapy

Registry NCT03374956

Phase Phase 3

Status Completed

Enrollment 193

Start 2017-12-11

Primary completion 2022-05-26

Study completion 2022-05-26

Intervention group

Regimen daily

Population Obesity

deaths

Control Group

Regimen daily

Population Obesity

deaths

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Registry NCT05952882

Phase Phase 3

Enrollment 188

Start 2023-11-01

Primary completion 2025-12-31

Study completion 2025-12-31

Catalyst Primary completion. 2025-12-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

LIME 3mg/1500mg

Dose 1500mg

Regimen once daily

Weeks 2

Population Polycystic Ovary Syndrome; Obesity; Infertility, Female

MET 1500mg

Dose 1500mg

Regimen once daily

Weeks 2

Population Polycystic Ovary Syndrome; Obesity; Infertility, Female

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Registry NCT05965908

Phase Phase 3

Status Completed

Enrollment 183

Start 2024-08-01

Primary completion 2025-11-30

Study completion 2025-12-30

Catalyst Primary completion. 2025-11-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

liraglutide

Regimen weekly

Weeks 2

Population Polycystic Ovary

metformin

Regimen once daily

Weeks 2

Population Polycystic Ovary

control

Regimen once daily

Weeks 2

Population Polycystic Ovary

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Registry NCT01234649

Phase Phase 3

Status Completed

Enrollment 153

Start 2011-08-11

Primary completion 2019-04-24

Study completion 2019-06-14

Metformin XR plus liraglutide

Weeks 84

Comparator placebo

Population Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation

percent change in body weight, -7.2 %, week 84Stale

deaths

participants with nausea, 29 participantsStale

participants with diarrhea, 14 participantsStale

Metformin XR plus placebo

Weeks 84

Population Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Disorder of Glucose Regulation

percent change in body weight, -3.1 %, week 84Stale

deaths

participants with nausea, 2 participantsStale

participants with diarrhea, 13 participantsStale

LYDIA

Registry NCT02043054

EudraCT 2012-002422-78

Phase Phase 3

Status Completed

Enrollment 90

Start 2013-12-16

Primary completion 2017-09-02

Study completion 2017-09-29

Liraglutide

Regimen daily

Weeks 26

Population Type 2 Diabetes Mellitus; Cardiovascular Disease

Sitagliptin

Regimen daily

Weeks 26

Population Type 2 Diabetes Mellitus; Cardiovascular Disease

SAXAPCOS

Registry NCT03480022

Phase Phase 3

Status Completed

Enrollment 88

Start 2018-09-26

Primary completion 2021-02-22

Study completion 2021-05-19

Liraglutide Pen Injector (Saxenda)

Regimen daily

Weeks 1

Comparator placebo

Population Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android

percent change in body weight, 5.7 %, week 32Stale

deaths

participants with nausea, 14 participantsStale

participants with vomiting, 5 participantsStale

participants with diarrhea, 4 participantsStale

Placebo liraglutide pen injector

Regimen daily

Weeks 1

Population Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android

percent change in body weight, 1.4 %, week 32Stale

deaths

participants with nausea, 3 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhea, 0 participantsStale

Liraglutide In Overweight Patients With Type 1 Diabetes

Registry NCT01753362

Phase Phase 3

Status Completed

Enrollment 84

placebo

Regimen daily

Weeks 26

Population Type 1 Diabetes

deaths

liraglutide

Regimen daily

Weeks 26

Comparator placebo

Population Type 1 Diabetes

deaths

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Registry NCT04775082

EudraCT 2020-000546-34

Phase Phase 3

Status Active, not recruiting

Enrollment 78

Start 2021-03-04

Primary completion 2023-08-01

Study completion 2027-02-08

Liraglutide 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 96

Comparator placebo

Population Obesity

Placebo

Regimen once daily

Weeks 96

Population Obesity

Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients

Registry NCT03986008

Phase Phase 3

Enrollment 60

Start 2019-12-01

Primary completion 2021-12-23

Study completion 2021-12-23

Benaglutide

Regimen once daily

Population Obesity

Liraglutide

Regimen once daily

Population Obesity

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Registry NCT02527200

EudraCT 2014-004415-37

Phase Phase 3

Status Completed

Enrollment 56

Start 2015-11-09

Primary completion 2020-11-04

Study completion 2020-11-19

Liraglutide

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -1.7 %Stale

change in HbA1c, -0.2 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 1 participantsStale

participants with vomiting, 2 participantsStale

Placebo

Population Metabolism and Nutrition Disorder; Obesity

percent change in body weight, -0.7 %Stale

change in HbA1c, 0 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 2 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

CGH-LiNASH

Registry NCT02654665

Phase Phase 3

Enrollment 36

Liraglutide

Regimen once daily

Weeks 6

Population Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH)

Bariatric Surgery

Regimen once daily

Weeks 6

Population Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH)

Diet modification and exercise

Regimen once daily

Weeks 6

Population Non-alcoholic Fatty Liver Disease (NAFLD); Weight Loss; Non-alcoholic Steatohepatitis (NASH)

i-LAB

Registry NCT02718950

Phase Phase 3

Enrollment 20

Liraglutide 3.0 mg

Dose 3.0 mg

Population Obesity; Type 2 Diabetes Mellitus

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

Registry NCT04325581

Phase Phase 3

Status Completed

Enrollment 16

Start 2016-08-01

Primary completion 2018-12-31

Study completion 2018-12-31

Post LSG with Liraglutude

Regimen once daily

Comparator placebo

Population Weight Loss

Post LSG without Liraglutide

Regimen once daily

Population Weight Loss

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Registry NCT02417103

Phase Phase 3

Status Terminated

Enrollment 2

GLP-1 (Liraglutide)

Regimen daily

Weeks 9

Comparator placebo

Population Obesity

Placebo Comparator

Regimen daily

Weeks 9

Population Obesity

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Registry NCT04683237

Phase Phase 2/3

Status Withdrawn

Enrollment 0

Start 2021-03-20

Primary completion 2025-11-30

Study completion 2026-11-30

Catalyst Primary completion. 2025-11-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

MA alone

Regimen daily

Population Atypical Endometrial Hyperplasia; Obese; Fertility Issues

MA+liraglutide

Regimen daily

Population Atypical Endometrial Hyperplasia; Obese; Fertility Issues

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Registry NCT02453711

EudraCT 2014-001540-38

Phase Phase 2

Status Completed

Enrollment 957

Start 2015-10-01

Primary completion 2017-03-30

Study completion 2017-04-12

Sema 0.05 mg

Dose 0.05 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.1 mg

Dose 0.1 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.2 mg

Dose 0.2 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.3 mg

Dose 0.3 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.4 mg

Dose 0.4 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.3 mg (fast dose escalation)

Dose 0.3 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Sema 0.4 mg (fast dose escalation)

Dose 0.4 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Placebo Sema 0.05 mg

Dose 0.05 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 53.5 %, week 52Stale

participants with at least 10 percent body weight loss, 18.94 %, week 52Stale

deaths

participants with diarrhoea, 20 participantsStale

participants with nausea, 32 participantsStale

participants with vomiting, 8 participantsStale

Placebo Sema 0.1 mg

Dose 0.1 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 67.49 %, week 52Stale

participants with at least 10 percent body weight loss, 36.57 %, week 52Stale

deaths

participants with diarrhoea, 25 participantsStale

participants with nausea, 42 participantsStale

participants with vomiting, 18 participantsStale

Placebo Sema 0.2 mg

Dose 0.2 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 74.91 %, week 52Stale

participants with at least 10 percent body weight loss, 55.95 %, week 52Stale

deaths

participants with diarrhoea, 35 participantsStale

participants with nausea, 45 participantsStale

participants with vomiting, 24 participantsStale

Placebo Sema 0.3 mg

Dose 0.3 mg

Regimen once daily

Population Metabolism and Nutrition Disorder; Obesity

Placebo Sema 0.4 mg

Dose 0.4 mg

Regimen once daily

Population Metabolism and Nutrition Disorder; Obesity

Placebo Sema 0.3 mg (fast dose escalation)

Dose 0.3 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 80.52 %, week 52Stale

participants with at least 10 percent body weight loss, 57.76 %, week 52Stale

deaths

participants with diarrhoea, 27 participantsStale

participants with nausea, 43 participantsStale

participants with vomiting, 11 participantsStale

Placebo Sema 0.4 mg (fast dose escalation)

Dose 0.4 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 82.52 %, week 52Stale

participants with at least 10 percent body weight loss, 64.61 %, week 52Stale

deaths

participants with diarrhoea, 38 participantsStale

participants with nausea, 49 participantsStale

participants with vomiting, 17 participantsStale

Placebo Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 52

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 66.12 %, week 52Stale

participants with at least 10 percent body weight loss, 33.98 %, week 52Stale

deaths

participants with diarrhoea, 29 participantsStale

participants with nausea, 46 participantsStale

participants with vomiting, 11 participantsStale

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Registry NCT03235050

Phase Phase 2

Status Completed

Enrollment 834

Start 2017-08-02

Primary completion 2018-05-03

Study completion 2019-06-14

MEDI0382 low dose + Metformin

Regimen daily

Comparator placebo

Population Diabetes Mellitus, Type 2

MEDI0382 mid dose + Metformin

Regimen daily

Comparator placebo

Population Diabetes Mellitus, Type 2

MEDI0382 high dose + Metformin

Regimen daily

Comparator placebo

Population Diabetes Mellitus, Type 2

Placebo + Metformin

Regimen daily

Weeks 14

Population Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 3 %, week 14Stale

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 5 participantsStale

Liraglutide + Metformin

Regimen daily

Comparator placebo

Population Diabetes Mellitus, Type 2

deaths

participants with diarrhoea, 4 participantsStale

participants with nausea, 17 participantsStale

participants with vomiting, 3 participantsStale

MEDI0382 100 mcg

Dose 100 mcg

Regimen daily

Weeks 14

Population Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 18 %, week 14Stale

deaths

participants with diarrhoea, 13 participantsStale

participants with nausea, 23 participantsStale

participants with vomiting, 10 participantsStale

MEDI0382 200 mcg

Dose 200 mcg

Regimen daily

Weeks 14

Population Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 65 %, week 14Stale

deaths

participants with diarrhoea, 49 participantsStale

participants with nausea, 85 participantsStale

participants with vomiting, 51 participantsStale

MEDI0382 300 mcg

Dose 300 mcg

Regimen daily

Weeks 14

Population Diabetes Mellitus, Type 2

participants with at least 5 percent body weight loss, 92 %, week 14Stale

deaths

participants with diarrhoea, 28 participantsStale

participants with nausea, 105 participantsStale

participants with vomiting, 43 participantsStale

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Registry NCT03856047

EudraCT 2018-001945-14

Phase Phase 2

Status Completed

Enrollment 706

Start 2019-03-01

Primary completion 2020-03-02

Study completion 2021-03-25

NNC0174-0833, 4.5 mg

Dose 4.5 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Overweight; Obesity

NNC0174-0833, 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Overweight; Obesity

NNC0174-0833, 1.2 mg

Dose 1.2 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Overweight; Obesity

NNC0174-0833, 0.6 mg

Dose 0.6 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Overweight; Obesity

NNC0174-0833 0.3 mg

Dose 0.3 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Overweight; Obesity

Placebo 2.4 mg (NNC0174-0833)

Dose 2.4 mg

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -9.5 %Stale

participants with at least 5 percent body weight loss, 74.12 %, week 26Stale

participants with at least 10 percent body weight loss, 43.97 %, week 26Stale

change in HbA1c, -0.1 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 18 participantsStale

participants with nausea, 32 participantsStale

participants with vomiting, 9 participantsStale

Placebo 4.5 mg (NNC0174-0833)

Dose 4.5 mg

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -10.8 %Stale

participants with at least 5 percent body weight loss, 88.74 %, week 26Stale

participants with at least 10 percent body weight loss, 53.49 %, week 26Stale

change in HbA1c, -0.1 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 7 participantsStale

participants with nausea, 47 participantsStale

participants with vomiting, 8 participantsStale

Placebo 1.2 mg (NNC0174-0833)

Dose 1.2 mg

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -8.5 %Stale

participants with at least 5 percent body weight loss, 75.84 %, week 26Stale

participants with at least 10 percent body weight loss, 35.79 %, week 26Stale

change in HbA1c, -0.1 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 8 participantsStale

participants with nausea, 37 participantsStale

participants with vomiting, 5 participantsStale

Placebo 0.6 mg (NNC0174-0833)

Dose 0.6 mg

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -6.9 %Stale

participants with at least 5 percent body weight loss, 61.98 %, week 26Stale

participants with at least 10 percent body weight loss, 24.06 %, week 26Stale

change in HbA1c, -0.1 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 27 participantsStale

participants with vomiting, 6 participantsStale

Placebo 0.3 mg (NNC0174-0833)

Dose 0.3 mg

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -6.1 %Stale

participants with at least 5 percent body weight loss, 57.47 %, week 26Stale

participants with at least 10 percent body weight loss, 15.28 %, week 26Stale

change in HbA1c, 0 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 15 participantsStale

participants with nausea, 20 participantsStale

participants with vomiting, 6 participantsStale

Liraglutide 3.0 mg

Dose 3.0 mg

Regimen once daily

Weeks 26

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -8.5 %Stale

change in HbA1c, -0.3 Percentage point of HbA1cStale

Placebo 3.0 mg (Liraglutide)

Dose 3.0 mg

Regimen once daily

Weeks 26

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -3 %Stale

participants with at least 5 percent body weight loss, 76.16 %, week 26Stale

participants with at least 10 percent body weight loss, 39.43 %, week 26Stale

change in HbA1c, -0.1 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 18 participantsStale

participants with nausea, 39 participantsStale

participants with vomiting, 20 participantsStale

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Registry NCT00422058

EudraCT 2006-004481-13

Phase Phase 2

Status Completed

Enrollment 564

Start 2007-01-10

Primary completion 2007-09-13

Study completion 2009-04-30

Lira placebo/Lira 2.4 mg/Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Population Metabolism and Nutrition Disorder; Obesity

change in HbA1c, 5.6 percentage (%) of total haemoglobinStale

participants with diarrhoea, 20 participantsStale

participants with nausea, 29 participantsStale

participants with vomiting, 6 participantsStale

Lira 1.2 mg/Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

change in HbA1c, 5.58 percentage (%) of total haemoglobinStale

participants with diarrhoea, 15 participantsStale

participants with nausea, 35 participantsStale

participants with vomiting, 12 participantsStale

Lira 1.8 mg/Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

change in HbA1c, 5.6 percentage (%) of total haemoglobinStale

participants with diarrhoea, 16 participantsStale

participants with nausea, 34 participantsStale

participants with vomiting, 13 participantsStale

Lira 2.4 mg/Lira 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Liraglutide 3.0 mg

Dose 3.0 mg

Regimen once daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

change in HbA1c, 5.57 percentage (%) of total haemoglobinStale

participants with diarrhoea, 18 participantsStale

participants with nausea, 47 participantsStale

participants with vomiting, 13 participantsStale

Orlistat

Regimen daily

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

change in HbA1c, 5.55 percentage (%) of total haemoglobinStale

participants with diarrhoea, 33 participantsStale

participants with nausea, 8 participantsStale

participants with vomiting, 0 participantsStale